US Patent

US11007206 — Cyclic boronic acid ester derivatives and therapeutic uses thereof

Method of Use · Assigned to Melinta Subsidiary Corp · Expires 2031-08-08 · 5y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of treating bacterial infections by administering a cyclic boronic acid ester compound in combination with a carbapenem antibacterial agent like Biapenem.

USPTO Abstract

Method of treating or ameliorating a bacterial infection comprising administering a composition comprising a cyclic boronic acid ester compound in combination with a carbapenem antibacterial agent such as Biapenem, and the pharmacokinetics studies thereof are provided.

Drugs covered by this patent

Merrem (Meropenem) · Pfizer

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3128`	—	Merrem

Patent Metadata

Patent number: US11007206
Jurisdiction: US
Classification: Method of Use
Expires: 2031-08-08
Drug substance claim: No
Drug product claim: No
Assignee: Melinta Subsidiary Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.